Medical Device | January 19, 2022
ICMR approves Krivida Novus RT-PCR kit
Krivida Novus can detect the Omicron variant and its sub-lineages in 45 minutes
Krivida Novus can detect the Omicron variant and its sub-lineages in 45 minutes
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
In-house wet testing with live Omicron virus demonstrated that the Antigen test detects the Omicron variant with comparable sensitivity to other variants
The study will be published on the pre-print server, medRXiv, shortly
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Recent Study by Columbia University finds Mylab’s CoviSelf can detect the Omicron variant successfully
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
Subscribe To Our Newsletter & Stay Updated
